fda changes to semaglutide just got FDA-approved for kidney disease. This everything., January 2025. The approved semaglutide (Ozempic/Wegovy) for a new indication: reducing kidney disease progression in Navigating Compounded Semaglutide: What Health

Full clinical and market details here: Preapared by HEALTHCARE ALLIANCE VIETNAM #GLP1 #ObesityTreatment #WeightLossTherapy #Pharma #NovoNordisk #HealthcareInnovation #Cardiometabolic #Biopharma #HealthcareAlliance #HealthcareInsights To view or add a comment, sign in Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved once-daily Wegovy pill, the first oral GLP-1 medicine for obesity in the US.3 Wegovy pill is used with a reduced calorie diet and increased physical activity for adults with obesity, or with overweight who also have weight-related medical problems, to help them lose weight and keep it off.3 Wegovy pill is also indicated to reduce the risk of major adverse cardiovascular events (MACE) such as death, heart attack, or stroke in adults with overweight or obesity and established cardiovascular disease

Additional cartridges are available for purchase

Follow-up timing depends on clinic protocols, but initial contact within a few weeks of starting therapy and periodic checks every few months is a common model

Don't boil it or microwave it

AEDG peptide regulation of the expression of human circadian rhythm genes upon accelerated aging of the pineal gland